Evidence map›Paper›PMID 33852029›Full record

ReviewDer Nervenarzt2022

[Chemsex : A new challenge in addiction medicine and infectious diseases].

Marcus Gertzen, Moritz Strasburger, Jan Geiger, Cornelia Rosenberger, Solveig Gernun, Johanna Schwarz, Andrea Rabenstein, Tobias Rüther

Abstract readReview
PubMed Publisher
In one paragraph

Review in Der Nervenarzt, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed.

  1. Review
  2. Article
  3. Observational
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Marcus GertzenKlinik für Psychiatrie, Psychotherapie und Psychosomatik der Universität Augsburg, Medizinische Fakultät, Bezirkskrankenhaus Augsburg, Dr.-Mack-Str. 1, 86156, Augsburg, Deutschland. marcus.gertzen@bkh-augsburg.de.
Moritz StrasburgerKlinik für Psychiatrie und Psychotherapie, LMU Klinikum München, München, Deutschland.
Jan GeigerSchwules Kommunikations- und Kulturzentrum München e. V., München, Deutschland.
Cornelia RosenbergerKlinik für Psychiatrie und Psychotherapie, LMU Klinikum München, München, Deutschland.
Solveig GernunKlinik für Psychiatrie und Psychotherapie, LMU Klinikum München, München, Deutschland.
Johanna SchwarzKlinik für Psychiatrie und Psychotherapie, LMU Klinikum München, München, Deutschland.
Andrea RabensteinKlinik für Psychiatrie und Psychotherapie, LMU Klinikum München, München, Deutschland.
Tobias RütherKlinik für Psychiatrie und Psychotherapie, LMU Klinikum München, München, Deutschland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundRecently there has been an increase in reports of the phenomenon called chemsex, a subform of sexualized substance use. Chemsex is a neologism consisting of the two terms "chemicals" and "sex". It describes the use of methamphetamine, γ‑hydroxybutyrate/γ-butyrolactone (GHB/GBL), mephedrone and sometimes other substances in a sexual context, especially by men who have sex with men (MSM). Chemsex has been described as a significant risk factor for mental and physical diseases.

objectiveDue to the increasing importance of the phenomenon and the significantly increased number of publications on the subject, this article provides an overview of the current and relevant literature. The aim is to raise awareness on this topic among practitioners and researchers and thus to facilitate access to the help system for those affected.

methodA literature search was conducted in PubMed/Medline, Cochrane and Embase for the terms "chemsex", "sexualized drug use" and "slamming. A total of 22 articles were identified as being relevant.

resultsIn the published literature on chemsex the current focus lies on somatic comorbidities. There is a significantly increased risk of sexually transmitted diseases. Mental illnesses such as depression, substance-induced psychosis and addiction also appear to be a significant consequence of chemsex. An individualized and specialized treatment approach is not yet established. DISCUSSION: The complexity of chemsex with its psychiatric and somatic aspects does not yet appear to be sufficiently reflected by the current data situation; however, due to the mutual influence of these different comorbidities, this patient clientele appears to be particularly at risk in the absence of a specialized treatment option, which is why further research on this topic is needed.

Indexed as

Addiction MedicineSexual and Gender MinoritiesSexually Transmitted DiseasesSubstance-Related DisordersHomosexuality, MaleHumansMaleSexual BehaviorAddictionChemsexMethamphetamineMSMSexualized substance use

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.